No Abstract Assistant Managing EditorDanish biotech firm Zealand Pharma A/S partnered with Helsinn Healthcare in a potential €140 million (US$176.8 million) deal to develop its early clinical-stage glucagon-like peptide (GLP)-2 receptor agonist, ZP1846, in chemotherapy-induced diarrhea (CID).Under the terms, Zealand granted Helsinn worldwide rights to the compound, except for the Nordic countries, where Zealand retains marketing rights.